West Cancer Center | Strategic Alliance Partners

Latest from West Cancer Center


Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

February 25, 2021

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

Trastuzumab Deruxtecan Slated for Study in HER2+ Gastric/GEJ Cancer

February 15, 2021

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

Lung Cancer: Chaired by Jason Porter, MD

January 26, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of lung cancer.